Federated Hermes
BMRN icon

Federated Hermes’s BioMarin Pharmaceuticals BMRN Stock Holding History

Federated Hermes’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,000
Closed -$1.82M – 2141
2017
Q2 		$1.82M Hold
20,000
– – 0.01% 961
2017
Q1 		$1.76M Hold
20,000
– – 0.01% 956
2016
Q4 		$1.65M Buy
+20,000
New +$1.72M 0.01% 944

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Federated Hermes's BMRN Position: Q2 2026 in Review

Federated Hermes increased its BioMarin Pharmaceuticals (BMRN) stake by 0.94% in Q2 2026, buying an estimated $83.4K and bringing the position to 163,619 shares worth $9.36M. The position accounts for 0.01% of the portfolio, ranked #706.

Federated Hermes first reported a position in BMRN in Q1 2015 and has held it in 27 quarters since. The position peaked at $17.8M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Federated Hermes held 163,619 shares of BioMarin Pharmaceuticals worth $9.36M as of Q2 2026.
  • Federated Hermes bought 1,522 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $83.4K.
  • BioMarin Pharmaceuticals made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #706 holding.
  • Federated Hermes first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 27 quarters since.
  • Federated Hermes's BioMarin Pharmaceuticals position peaked at $17.8M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.